What is a comprehensive overview of rheumatoid arthritis, including its clinical presentation, diagnosis, and treatment?

Rheumatoid Arthritis: Comprehensive Overview

Rheumatoid arthritis is the most common autoimmune disease affecting joints, requiring early aggressive treatment with disease-modifying antirheumatic drugs (DMARDs) targeting remission or low disease activity to prevent irreversible joint destruction, disability, and premature mortality. 1, 2

Epidemiology and Disease Burden

RA affects approximately 1% of the global population, with higher prevalence in persons of European or Asian ancestry 1. The typical age of onset is around 55 years, though it can develop at any age. Women face substantially higher risk than men—lifetime risk is 3.6% in women versus 1.7% in men 1.

The disease carries severe consequences for morbidity and mortality:

• Life expectancy is shortened by 3-5 years, particularly in patients with extra-articular manifestations 1
• More than one-third of patients experience work disability 1
• Employment rates decline rapidly: 80% working at 2 years, only 68% at 5 years 1
• Cardiovascular disease is the leading cause of death, with risk comparable to diabetes mellitus 3

Clinical Presentation

Articular Manifestations

The hallmark presentation is symmetric polyarthritis with joint swelling, predominantly affecting the hands and feet, though any appendicular joint may be involved 1.

Key diagnostic features include:

• Morning stiffness lasting ≥1 hour 1
• Symmetric joint involvement
• Small and large joint polyarthritis 4
• Progressive joint destruction if untreated

Extra-Articular Manifestations

These indicate severe disease and worse prognosis 1:

• Subcutaneous rheumatoid nodules (characteristic finding)
• Interstitial lung disease (affects 10-15% of patients, associated with significant mortality) 5
• Vasculitis (rheumatoid vasculitis, though becoming rarer with better disease control) 3
• Inflammatory eye disease (including scleritis, which can be severe) 1, 3
• Cardiac involvement
• Hematologic complications (pure red cell aplasia, myelodysplasia) 3

Important Comorbidities

• Cardiovascular disease (leading cause of death) 3
• Osteoporosis (treatment and disease-related) 1
• Infections (increased risk, largely treatment-related) 3
• Fibromyalgia, anxiety, depression, and fatigue 3

Diagnosis

Early diagnosis is critical—timely intervention reduces disease burden and improves long-term outcomes 1, 2.

Classification Criteria

Diagnosis requires 1:

1. Confirmed synovitis in ≥1 joint
2. Absence of alternative diagnosis that better explains the synovitis
3. Score ≥6 points across four domains:
   • Number and site of involved joints (0-5 points)
   • Serologic abnormality (0-3 points)
   • Elevated acute-phase reactants (0-1 point)
   • Symptom duration (0-1 point)

Serologic Testing

• Anti-citrullinated protein antibody (ACPA): High specificity (90%), moderate sensitivity (60%) 1
• Rheumatoid factor (RF): Lower specificity (70%), sensitivity increases to 80% with prolonged disease 1

Disease Activity Assessment

Composite measures must be used to guide treatment decisions 1, 2, 6:

Recommended tools:

• DAS28 (Disease Activity Score-28): EULAR-recommended 1
• SDAI (Simplified Disease Activity Index): No complex calculations required 1
• CDAI (Clinical Disease Activity Index): Does not require acute-phase reactant measurement, most practical for clinical use 1

Monitoring frequency 2:

• High/moderate disease activity: Monthly assessment
• Low disease activity or remission: Every 3-6 months

Treatment Strategy

Overarching Principles

The modern approach to RA management has fundamentally changed 1, 2, 6:

Core treatment principles 2:

1. Early evaluation, diagnosis, and management are mandatory
2. Shared decision-making between patient and rheumatologist
3. Treat-to-target strategy: Systematic approach with frequent monitoring and treatment modification to achieve remission or low disease activity 6, 7
4. Reassess within 3 months for efficacy and tolerability 2
5. Target must be achieved by 6 months, or therapy must be adjusted 6

Phase I: Initial Treatment

For DMARD-naive patients with active RA, start with methotrexate (MTX) as first-line therapy 2, 6, 8. MTX remains the preferred conventional synthetic DMARD (csDMARD) due to superior efficacy and safety profile 8.

Alternative csDMARDs (if MTX contraindicated or not tolerated) 2, 6:

• Leflunomide (similar efficacy to MTX) 8
• Sulfasalazine 2, 6

Glucocorticoid bridging therapy 6:

• Short-term glucocorticoids should be added when initiating or changing csDMARDs
• Must be tapered rapidly, aiming for discontinuation within approximately 3 months 6
• Failure to maintain target on glucocorticoid taper indicates need for biologic or targeted synthetic DMARD 6

Critical caveat: Minimize glucocorticoid use due to serious adverse effects including infections, cardiovascular events, and osteoporosis 1, 2.

Phase II: Escalation for Inadequate Response

If target not achieved by 3-6 months on csDMARD, add a biologic DMARD (bDMARD) or targeted synthetic DMARD (tsDMARD) 2, 6, 9.

Choice depends on prognostic factors 6:

Poor prognostic factors present (RF/ACPA positive, especially high levels; high disease activity; early joint damage; failure of 2 csDMARDs):

• Add bDMARD or JAK inhibitor (tsDMARD) to MTX 6

Poor prognostic factors absent:

• May try second csDMARD or triple therapy (hydroxychloroquine + sulfasalazine + MTX or leflunomide) 6

bDMARD Options 2, 6, 9:

• TNF inhibitors: Adalimumab, certolizumab pegol, etanercept, golimumab, infliximab
• IL-6 receptor inhibitors: Tocilizumab, sarilumab
• T-cell costimulation inhibitor: Abatacept
• Anti-CD20 antibody: Rituximab (reserved for TNF inhibitor failures or lymphoproliferative disorders) 2

tsDMARD Options (JAK inhibitors) 2, 9:

• Tofacitinib, baricitinib, filgotinib, upadacitinib

Important safety considerations for JAK inhibitors 9:

• Increased risk of major cardiovascular events (MACEs)
• Increased risk of malignancies
• Increased risk of thromboembolic events
• Careful risk assessment required before initiating 9

Phase III: Switching After bDMARD/tsDMARD Failure

If first bDMARD or JAKi fails, switch to any other bDMARD (from different or same class) or JAKi (after considering risks) 6, 9.

Switching strategies 8:

• Cycling: Switch to different drug with same mechanism of action
• Swapping: Switch to drug with different mechanism of action

Tapering in Sustained Remission

Once sustained remission achieved for ≥6 months, DMARDs may be tapered 2, 6, 9.

Critical warnings:

• Tapering must be gradual (dose reduction or increased dosing interval) 2
• Stopping therapy often leads to flare 9
• Continue close monitoring during taper

Long-Term Management Goals

Primary objectives 1:

1. Maximize long-term health-related quality of life
2. Control symptoms (pain, inflammation, stiffness, fatigue)
3. Prevent structural joint damage
4. Normalize function and social participation
5. Prevent comorbidities: Cardiovascular disease, osteoporosis, infections

Target outcomes 2, 7:

• Primary target: Clinical remission (absence of signs and symptoms of significant inflammatory disease activity) 7
• Acceptable alternative: Low disease activity (particularly in established, long-standing disease) 7

Common Pitfalls to Avoid

1. Delayed referral to rheumatology: Primary care physicians must recognize early RA and refer promptly 4
2. Inadequate disease activity monitoring: Must use validated composite measures, not individual assessments alone 1
3. Prolonged glucocorticoid use: Increases mortality risk from infections, cardiovascular disease, and malignancies 1
4. Failure to escalate therapy: If target not achieved by 6 months, treatment must be intensified 2, 6
5. Ignoring cardiovascular risk: RA patients have diabetes-equivalent cardiovascular risk requiring aggressive management 3
6. Premature treatment discontinuation: Even in remission, stopping DMARDs frequently causes flares 9